This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by BOTHA, J. L. Articles by BROWN, J. C. Search for Related Content PubMed PubMed Citation Articles by BOTHA, J. L. Articles by BROWN, J. C.

Gastric Inhibitory Polypeptide (GIP) in Chronic Pancreatitis

Endocrine and Diabetes Research Unit, University of Cape Town, and the Department of Physiology, University of British Columbia Vancouver, Canada

The plasma gastric inhibitory polypeptide (GIP), pancreatic glucagon-like immunoreactivity (PGLI),andgutglucagon-likeimmunoreactivity (GGLI) responses to oral glucose have been measured in five patients with chronic pancreatitis (with diabetic glucose tolerance tests) and in matched nondiabetic controls. Plasma GIP levels rise rapidly after glucose ingestion before changes in circulating glucose and insulin concentration. Patients with pancreatitis have a greater than normal GIP response to oral glucose, which may account for the relatively unimpaired insulin response to oral glucose in these patients compared with that to iv glucose, as has been previously found. Patients with pancreatitis also have a paradoxical rise in PGLI and an exaggerated rise in GGLI concentration following oral glucose.

Received July 21, 1975.